Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 28;36(3):760–771. doi: 10.1038/s41375-021-01421-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Expression of immune-regulatory molecules was determined by flow cytometry analysis of peripheral blood mononuclear cells (PBMCs) isolated from Hodgkin lymphoma (HL) patients before therapy (BT, n = 72), sequential samples obtained 1 and 8 weeks after treatment initiation (TP1, n = 72 and TP2, n = 68) and after completion of treatment (TP3, n = 62). Samples containing ≤100 CD45⁺ cells were excluded. Selected plots showing PD1, TIGIT, Tim3, CTLA4, OX40, and ICOS expression on T cells of HL patients before therapy (BT) and during the course of therapy are depicted. B Significant up/ downregulation of co-inhibitory and co-stimulatory molecule expression on T cells, CD4 T cells, CD8 T cells, B cells, and NK cells of HL patients during therapy (T1–TP3) compared to the mean expression obtained from before therapy samples (n = 72). Significant differences of before therapy (BT) samples and samples during the course of therapy (TP1–TP3) were calculated by nonparametric Kruskal–Wallis test followed by Dunn’s post hoc test. Results are indicated by asterisks. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. When appropriate, mean ± SD is indicated.